This groundbreaking approach, rooted in historical milestones like “Coley’s toxins” [1] and, later, the identification of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), has consistently showcased the potential to redefine cancer treatment paradigms [2,3,4]. The gene discussed is CTLA4; the disease is cancer.